955985ca-7d97-4911-927a-3803e669a805
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 36
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.260
- MYC_TARGETS_V1+0.210
- HEDGEHOG_SIGNALING+0.200
- TGF_BETA_SIGNALING+0.200
- G2M_CHECKPOINT+0.180
- E2F_TARGETS+0.170
- ALLOGRAFT_REJECTION+0.160
- PANCREAS_BETA_CELLS+0.150
- UV_RESPONSE_DN+0.110
- MITOTIC_SPINDLE+0.050
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- HYPOXIA-0.360
- TNFA_SIGNALING_VIA_NFKB-0.310
- GLYCOLYSIS-0.270
- IL6_JAK_STAT3_SIGNALING-0.260
- INTERFERON_ALPHA_RESPONSE-0.240
- INTERFERON_GAMMA_RESPONSE-0.210
- APOPTOSIS-0.200
- DNA_REPAIR-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ce41f5d1-6e6d-4fc8-b8ed-a9479bcc8add | — | — | 0.789 |
| 2 | AUR-AG0M-TTP1-A-2-0-R-A741-41 | — | D | 0.786 |
| 3 | SRR12475135 | — | — | 0.773 |
| 4 | SRR10899974 | — | — | 0.765 |
| 5 | SRR934959 | — | — | 0.748 |
| 6 | TCGA-AC-A2QH-01B-04R-A22O-07 | — | D | 0.748 |
| 7 | TCGA-E9-A1N9-01A-11R-A14D-07 | — | C | 0.747 |
| 8 | SRR17866817 | — | — | 0.745 |
| 9 | SRR934948 | — | — | 0.733 |
| 10 | SJEPD030911_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.731 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |